The influence of patient´s perspective in therapeutic adherence in rheumatoid arthritis : a case study from Spain.

OBJECTIVES: The main objective is to study the contribution of illness and medication beliefs to treatment adherence in patients with rheumatoid arthritis. METHODS: the design was a cross-sectional study. The compliance Questionnaire for Rheumatology (CQR) was used to measure therapeutic adherence. The beliefs about medicines questionnaire (BMQ) and the brief illness perception questionnaire (IPQ-b) were used to assess patient's beliefs about medicines and about the disease. Other factors studied were treatment satisfaction, patient´s demographic and clinical characteristics. RESULTS: 144 patients were included in the study, 113 (78.4%) patients showed good treatment adherence. Patients with poor adherence presented higher scores in the BMQ harm domain (13±5 vs. 11±3, p= 0.013). Meanwhile, patients with good adherence presented higher scores in the necessity BMQ domain (21±3 vs. 20±3, p= 0.015), increased feeling of treatment control (8.8± 1.5 vs. 7.7± 2.1,p= 0.008), higher emotional response (6.2±3.1 vs. 4.8±3.4,p= 0.042) and a higher level of treatment satisfaction (77.2±12.4 vs. 69.9±12.5,p=0.004). In a multivariate analysis for each unit of increase in the score of BMQ´s harm domain, adherence was reduced by 20% (CI 95% 0.08-0.3, p= 0.001); for each unit of increase in treatment control item of the IPQ-b, adherence increased 1.4 times (CI 95% 1.1-1.8,p= 0.006); and for each unit of increase in the emotional response item of the IPQ-b, adherence increased 1.3 times (CI 95% 1.1-1.5,p= 0.002). CONCLUSION: in our cohort of RA patients, good adherence is associated with stronger treatment necessity perception, stronger feeling of treatment control, higher emotional response and higher level of treatment satisfaction; on the other side, patients with poor adherence had stronger beliefs of medicines as harmful substances.

Tratamiento con oxígeno hiperbárico en el fenómeno de Raynaud y las úlceras digitales asociadas a esclerosis sistémicas / Treatment of Raynaud Phenomenon and Ischemic Ulcers Associated to Systemic Sclerosis with Hyperbaric Oxygen

Presentamos 4pacientes con fenómeno de Raynaud asociado a esclerosis sistémica, 3de ellos con úlceras isquémicas, con intolerancia o falta de respuesta a tratamiento convencional, que presentaron mejoría tras tratamiento con oxígeno hiperbárico. Esta terapia ha sido utilizada para el tratamiento de úlceras de diversa etiología debido a su efecto cicatrizante, angiogénico, antiinflamatorio y antimicrobiano. El oxígeno hiperbárico podría constituir una alternativa terapéutica en pacientes con fenómeno de Raynaud o úlceras isquémicas de difícil manejo.(AU)

We describe 4patients with Raynaud's phenomenon associated with systemic sclerosis, 3with ischaemic ulcers, successfully treated with hyperbaric oxygen. This therapy has been useful in the treatment of chronic wounds due to its anti-inflammatory, antimicrobial and angiogenic effects. Hyperbaric oxygen treatment could be a therapeutic option in patients with Raynaud's phenomenon refractory to conventional treatment.(AU)

Treatment of Raynaud phenomenon and ischemic ulcers associated to systemic sclerosis with hyperbaric oxygen.

We describe 4 patients with Raynaud's phenomenon associated with systemic sclerosis, 3 with ischaemic ulcers, successfully treated with hyperbaric oxygen. This therapy has been useful in the treatment of chronic wounds due to its anti-inflammatory, antimicrobial and angiogenic effects. Hyperbaric oxygen treatment could be a therapeutic option in patients with Raynaud's phenomenon refractory to conventional treatment.

Treatment of Raynaud Phenomenon and Ischemic Ulcers Associated to Systemic Sclerosis with Hyperbaric Oxygen. / Tratamiento con oxígeno hiperbárico en el fenómeno de Raynaud y las úlceras digitales asociadas a esclerosis sistémicas.

We describe 4patients with Raynaud's phenomenon associated with systemic sclerosis, 3with ischaemic ulcers, successfully treated with hyperbaric oxygen. This therapy has been useful in the treatment of chronic wounds due to its anti-inflammatory, antimicrobial and angiogenic effects. Hyperbaric oxygen treatment could be a therapeutic option in patients with Raynaud's phenomenon refractory to conventional treatment.

Lupus eritematoso cutáneo inducido por la terapia biológica con antagonistas del factor de necrosis tumoral / Cutaneous lupus erythematosus induced by the treatment with tumor necrosis factor antagonists

No disponible

Osteonecrosis multifocal asociada a infección por el virus de la inmunodeficiencia humana / Multifocal osteonecrosis associated with human immunodeficiency virus infection

La osteonecrosis ha emergido en los últimos años como una complicación osteoarticular potencialmente discapacitante en pacientes con infección por el VIH. Existe una alta prevalencia de factores de riesgo tradicionales para el desarrollo de osteonecrosis en estos pacientes, pero también factores asociados a la infección por VIH en sí misma y el tratamiento antirretroviral de gran actividad. La osteonecrosis asociada a VIH suele afectar con mayor frecuencia a las caderas, con tendencia a la bilateralidad, pero la afección simultánea de 3 o más localizaciones (osteonecrosis multifocal) ha sido descrita de forma infrecuente. Presentamos el caso de un paciente varón de 49 años, con infección por el VIH de largo tiempo de evolución y tratamiento antirretroviral, que desarrolló osteonecrosis con afección simultánea de caderas, rodillas, tobillos y tarsos (AU)

The osteonecrosis has emerged in the last years as a potentially disabling osteoarticular complication in HIV-infected patients. There is a high prevalence of traditional risk factors for osteonecrosis development in these patients, but they also have factors associated to HIV infection in itself and the high activity antiretroviral therapy. The HIV-associated osteonecrosis often affects the hips, with a trend to bilaterally, but concomitant affection of 3 or more locations (multifocal osteonecrosis) has been infrequently reported. We present the case of a 49-years-old male patient, with long duration HIV infection and antiretroviral therapy, who developed osteonecrosis with concomitant affection of hips, knees, heels and tarsus (AU)

Osteoartropatía hipertrófica con acro-osteolisis y neoformación ósea en un paciente con hipertensión pulmonar primaria / Hypertrophic osteoarthropathy with acro-osteolysis in a patient with primary pulmonary hypertension

La osteoartropatía hipertrófica es una entidad caracterizada por la tríada de periostitis de huesos largos, acropaquias y artritis. Radiológicamente se distinguen 2 patrones; uno caracterizado por neoformación ósea que predomina en pacientes con patología pulmonar, y otro por acro-osteolisis que se asocia más frecuentemente con cardiopatías congénitas. Presentamos el caso de un varón de 30 años diagnosticado de hipertensión arterial pulmonar primaria desde los 2 años, que desarrolló una osteoartropatía hipertrófica con un patrón radiológico mixto (AU)

Hypertrophic osteoarthropathy is an entity characterized by a triad of periostitis of long bones, clubbing and arthritis. Radiologically there are two patterns, one characterized by new bone formation which predominates in patients with pulmonary disease, and another by acro-osteolysis that is most frequently associated with congenital heart disease. We report the case of a 30-year-old man diagnosed with primary pulmonary hypertension for two years, developing hypertrophic osteoarthropathy with a mixed radiological pattern (AU)

Multifocal osteonecrosis associated with human immunodeficiency virus infection.

The osteonecrosis has emerged in the last years as a potentially disabling osteoarticular complication in HIV-infected patients. There is a high prevalence of traditional risk factors for osteonecrosis development in these patients, but they also have factors associated to HIV infection in itself and the high activity antiretroviral therapy. The HIV-associated osteonecrosis often affects the hips, with a trend to bilaterally, but concomitant affection of 3 or more locations (multifocal osteonecrosis) has been infrequently reported. We present the case of a 49-years-old male patient, with long duration HIV infection and antiretroviral therapy, who developed osteonecrosis with concomitant affection of hips, knees, heels and tarsus.

Hypertrophic osteoarthropathy with acro-osteolysis in a patient with primary pulmonary hypertension.

Hypertrophic osteoarthropathy is an entity characterized by a triad of periostitis of long bones, clubbing and arthritis. Radiologically there are two patterns, one characterized by new bone formation which predominates in patients with pulmonary disease, and another by acro-osteolysis that is most frequently associated with congenital heart disease. We report the case of a 30-year-old man diagnosed with primary pulmonary hypertension for two years, developing hypertrophic osteoarthropathy with a mixed radiological pattern.

Chilblain lupus induced by TNF-α antagonists: a case report and literature review.

We report the case of a 72-year-old man with history of ankylosing spondylitis, who, during the treatment with infliximab, developed painful, erythematous-violaceous plaques with later development of ulcers on his feet associated with cold exposure. Concomitantly with the appearance of these lesions, he presented increased antinuclear antibodies (ANA) titers, positivity for anti-DNA and IgM anticardiolipin antibodies, low complement levels, polyclonal hypergammaglobulinemia, and lymphopenia. He was diagnosed of chilblain lupus induced by infliximab, this agent was withdrawn and initiated treatment for chilblains with improvement of lesions. On reviewing of the literature, we found seven reported cases of tumor necrosis factor α (TNF-α) antagonists-induced chilblain lupus, all in rheumatoid arthritis patients and four of them with clinical and immunological characteristics available are presented and compared with our case. Although it is infrequent, chilblain lupus forms part of the spectrum of TNF-α antagonists-induced lupus erythematosus; usually is limited to skin without progression to systemic lupus erythematosus; presents ANA, anti-DNA, and antinucleosome antibodies positivity as more frequent immunological alterations; and responds appropriately to the specific treatment, TNF-α antagonists withdrawal being not necessary in almost all cases.